Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objectives of the study were to assess the effects of fenofibrate on serum alkaline phosphatase, as a composite endpoint and on safety in participants with primary biliary cholangitis (PBC)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fenofibrate-ursodesoxycholic acid(UDCA) | Experimental | Fenofibrate 200 mg/day and UDCA 13-15mg/kg/day for 12 months |
|
| Placebo-UDCA | Placebo Comparator | 1 tablet/ day and UDCA 13-15mg/kg/day for 12 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fenofibrate | Drug | Fenofibrate 200 mg/day |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients with biochemical response | The normalisation of Alkaline Phosphatase | 48 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients having biochemical response | The normalisation of Alkaline Phosphatase at 4, 12, 24, and 36 weeks | 4, 12, 24 and 36weeks |
| Assessment of the pruritus | Change From Baseline in Pruritus as Assessed by Visual Analogue Scale (VAS) Total Score for Fatigue and Pruritus. (0-10, higher scores mean a worse outcome) |
Not provided
Inclusion Criteria:
Must have provided written informed consent
Age 18-75 years;
BMI 17-28 kg/m2
Male or female with a diagnosis of PBC, by at least two of the following criteria:
Incomplete response to UDCA defined by 1 x ULN< ALP <= 1.67 x ULN
Taking UDCA for at least 6 months (stable dose for ≥ 3 months) prior to Day 0
Exclusion Criteria:
Recurrent variceal bleeding, poorly controlled hepatic encephalopathy or refractory ascites.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The second hospital of Lanzhou University | Lanzhou | Gansu | China | |||
| Sun Yat-sen Memorial Hospital |
Not provided
| ID | Term |
|---|---|
| D008105 | Liver Cirrhosis, Biliary |
| ID | Term |
|---|---|
| D002780 | Cholestasis, Intrahepatic |
| D002779 | Cholestasis |
| D001649 | Bile Duct Diseases |
| D001660 | Biliary Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D011345 | Fenofibrate |
| ID | Term |
|---|---|
| D058607 | Fibric Acids |
| D058610 | Isobutyrates |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
1 tablet/ day |
|
| UDCA | Drug | UDCA 13-15mg/kg/day |
|
| 4, 12, 24, 36, and 48 weeks |
| Assessment of the fatigue | Change From Baseline in Fatigue as Assessed by Visual Analogue Scale (VAS) Total Score for Fatigue and Pruritus. (0-10, higher scores mean a worse outcome) | 4, 12, 24, 36, and 48 weeks |
| Percentage of patients having biological or clinical adverse events | Increase of creatinine, blood urea nitrogen, alanine aminotransferase and aspartate aminotransferase | 4, 12, 24, 36, and 48 weeks |
| Survival without transplantation and hepatic impairment | Occurrence of ascites, variceal bleeding, hepatic encephalopathy, liver-transplantation, or death | 48 weeks |
| Guangzhou |
| Guangdong |
| China |
| Jiangsu Province Hospital | Nanjing | Jiangsu | China |
| Nanjing Drum Tower Hospital | Nanjing | Jiangsu | China |
| Nanjing Second Hospital | Nanjing | Jiangsu | China |
| Shengjing Hospital Affiliated to China Medical University | Shenyang | Liaoning | China |
| Xijing Hospital | Xi'an | Shaanxi | China |
| Yan'an University Affiliated Hospital | Yan’an | Shanxxi | China |
| The Second Affiliated Hospital of Kunming Medical University | Kunming | Yunnan | China |
| Peking Union Medical College Hospital | Beijing | China |
| D004066 |
| Digestive System Diseases |
| D008107 | Liver Diseases |
| D008103 | Liver Cirrhosis |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D002264 |
| Carboxylic Acids |
| D009930 | Organic Chemicals |
| D010647 | Phenyl Ethers |
| D004987 | Ethers |
| D001577 | Benzophenones |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D010636 | Phenols |
| D007659 | Ketones |